The copper chelator tetrathiomolybdate (TTM) treatment hinders breast cancer metastasis by lowering Cu2+ levels and suppressing Mediator Of Cell Motility 1 (MEMO1) expression and angiogenesis [34]. Here, MEMO1 is linked to breast cancer.